Clinical Trial Update: Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating ivermectin in combination with balstilimab or pembrolizumab for metastatic triple-negative breast cancer, in Phase 1/2 and currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Balstilimab (balstilimab)
• IVERMECTIN (Ivermectin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yuan Yuan | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1, Phase 2 | Status: RECRUITING